» Articles » PMID: 6690090

Pretreatment of Human Colon Tumor Cells with DNA Methylating Agents Inhibits Their Ability to Repair Chloroethyl Monoadducts

Overview
Journal Carcinogenesis
Specialty Oncology
Date 1984 Jan 1
PMID 6690090
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

We have recently shown that a variety of human tumor cell lines are capable of preventing chloroethylnitrosourea (CNU)-induced DNA crosslinks, presumably by removing guanine O6-chloroethyl DNA monoadducts before crosslinks can form. Those cells capable of preventing crosslinking were of the Mer+ (Methylation repair) phenotype, and have been shown to be proficient at repair of O6-methyl-guanine adducts by the repair enzyme guanine-O6-methyl-transferase. Mer- tumor cell lines are: deficient at O6-methyl-guanine repair, incapable of preventing CNU interstrand crosslinking, and have recently been shown to lack the repair enzyme O6-methyl-transferase. We wish to report that pretreatment of Mer+ cells (HT-29 human colon carcinoma cells and IMR-90 normal human fibroblasts) with the DNA methylating agent MNNG, under conditions which should inactivate O6-methyl-transferase, apparently saturates the monoadduct repair system, and allows CNU to form interstrand crosslinks in these cells. This effect was also seen when MNU pretreatment was used, but not with MMS or streptozotocin. The formation of CNU-induced interstrand crosslinks following MNNG or MNU pretreatment was coincident with a dramatic increase in cytotoxicity as measured by colony formation assays. In contrast, cytotoxicity was only slightly increased when MMS or streptozotocin pretreatment was used.

Citing Articles

Targeting O⁶-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy.

Kaina B, Margison G, Christmann M Cell Mol Life Sci. 2010; 67(21):3663-81.

PMID: 20717836 PMC: 11115711. DOI: 10.1007/s00018-010-0491-7.


In vitro comparison of O4-benzylfolate modulated, BCNU-induced toxicity in human bone marrow using CFU-GM and tumor cell lines.

Behrsing H, Furniss M, Robillard K, Tomaszewski J, Parchment R Cancer Chemother Pharmacol. 2009; 65(6):1083-91.

PMID: 19727731 PMC: 8450814. DOI: 10.1007/s00280-009-1113-7.


Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells.

Lee S, Thatcher N, Dougal M, Margison G Br J Cancer. 1993; 67(2):216-21.

PMID: 8431354 PMC: 1968172. DOI: 10.1038/bjc.1993.42.


Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.

Lee S, Thatcher N, Crowther D, Margison G Br J Cancer. 1994; 69(3):452-6.

PMID: 8123472 PMC: 1968858. DOI: 10.1038/bjc.1994.82.


Drug resistance in brain tumors.

Feun L, Savaraj N, Landy H J Neurooncol. 1994; 20(2):165-76.

PMID: 7807193 DOI: 10.1007/BF01052726.